Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 2
1948 1
1950 6
1951 3
1952 1
1953 7
1954 1
1955 4
1956 2
1957 5
1958 3
1961 3
1962 1
1965 4
1966 1
1967 1
1972 1
1973 1
1976 3
1977 3
1978 6
1979 2
1980 2
1981 1
1982 4
1983 4
1984 1
1985 2
1986 3
1987 2
1988 5
1989 5
1990 2
1991 1
1992 7
1993 6
1994 9
1995 13
1996 9
1997 9
1998 9
1999 4
2000 4
2001 5
2002 3
2003 9
2004 7
2005 5
2006 10
2007 10
2008 4
2009 11
2010 10
2011 7
2012 12
2013 17
2014 14
2015 21
2016 23
2017 27
2018 14
2019 17
2020 32
2021 32
2022 36
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

450 results
Results by year
Filters applied: . Clear all
Page 1
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G; Biomarkers France contributors. Barlesi F, et al. Among authors: morin f. Lancet. 2016 Apr 2;387(10026):1415-1426. doi: 10.1016/S0140-6736(16)00004-0. Epub 2016 Jan 15. Lancet. 2016. PMID: 26777916 Free article.
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
Cortot AB, Audigier-Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, Dumont P, Pouessel D, Poulet C, Fontaine-Delaruelle C, Hiret S, Dixmier A, Renault PA, Becht C, Raffy O, Dayen C, Mazieres J, Pichon E, Langlais A, Morin F, Moro-Sibilot D, Besse B. Cortot AB, et al. Among authors: morin f. Eur J Cancer. 2020 May;131:27-36. doi: 10.1016/j.ejca.2020.02.022. Epub 2020 Apr 8. Eur J Cancer. 2020. PMID: 32276179 Clinical Trial.
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Zalcman G, et al. Among authors: morin f. Lancet. 2016 Apr 2;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719230 Clinical Trial.
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.
Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, Besse B. Mazieres J, et al. Among authors: morin f. J Clin Oncol. 2022 Mar 1;40(7):719-728. doi: 10.1200/JCO.21.01455. Epub 2022 Jan 24. J Clin Oncol. 2022. PMID: 35073148 Clinical Trial.
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup. Scherpereel A, et al. Among authors: morin f. Lancet Oncol. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16. Lancet Oncol. 2019. PMID: 30660609 Clinical Trial.
Animal models of systemic sclerosis.
Morin F, Kavian N, Batteux F. Morin F, et al. Curr Pharm Des. 2015;21(18):2365-79. doi: 10.2174/1381612821666150316120338. Curr Pharm Des. 2015. PMID: 25777753 Review.
Ethical and Social Aspects of Neurorobotics.
Aicardi C, Akintoye S, Fothergill BT, Guerrero M, Klinker G, Knight W, Klüver L, Morel Y, Morin FO, Stahl BC, Ulnicane I. Aicardi C, et al. Among authors: morin fo. Sci Eng Ethics. 2020 Oct;26(5):2533-2546. doi: 10.1007/s11948-020-00248-8. Sci Eng Ethics. 2020. PMID: 32700245 Free PMC article.
Hypothalamic glucose-sensing: role of Glia-to-neuron signaling.
Tonon MC, Lanfray D, Castel H, Vaudry H, Morin F. Tonon MC, et al. Among authors: morin f. Horm Metab Res. 2013 Dec;45(13):955-9. doi: 10.1055/s-0033-1355357. Epub 2013 Sep 23. Horm Metab Res. 2013. PMID: 24062091 Review.
Pineal function: impact of microarray analysis.
Klein DC, Bailey MJ, Carter DA, Kim JS, Shi Q, Ho AK, Chik CL, Gaildrat P, Morin F, Ganguly S, Rath MF, Møller M, Sugden D, Rangel ZG, Munson PJ, Weller JL, Coon SL. Klein DC, et al. Among authors: morin f. Mol Cell Endocrinol. 2010 Jan 27;314(2):170-83. doi: 10.1016/j.mce.2009.07.010. Epub 2009 Jul 19. Mol Cell Endocrinol. 2010. PMID: 19622385 Free PMC article. Review.
450 results